These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38758423)

  • 1. Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients.
    Erduran F; Adışen E; Emre S; Hayran Y; Başkan EB; Yazıcı S; Bilgiç A; Alpsoy E; Günaydın SD; Elmas L; Akyol M; Güner R; Arıca DA; Aypek Y; Ergun T; Karavelioğlu D; Yazıcı AC; Aydoğan K; Bayramgürler D; Kıran R; Erdoğan HK; Acer E; Aktaş A
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1547-1560. PubMed ID: 38758423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
    Jacobsen A; Olabi B; Langley A; Beecker J; Mutter E; Shelley A; Worley B; Ramsay T; Saavedra A; Parker R; Stewart F; Pardo Pardo J
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013130. PubMed ID: 35274741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinico- Therapeutic Study of Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and Prognostic Significance of SCORTEN in Indian Patients.
    Jangid NC; Choudhary AN; Shah BJ; Shah SR; Vyas HR; Mistry D
    Indian J Dermatol; 2024; 69(1):24-31. PubMed ID: 38572027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
    Chen J; Wang B; Zeng Y; Xu H
    Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicoetiological Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Spectrum and the Correlation of SCORTEN with Prognosis.
    Kanagarajan A; Murthy AB; Moni PK; Palanivel N
    Indian J Dermatol; 2023; 68(1):25-33. PubMed ID: 37151260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
    Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
    Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
    Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
    Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
    Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
    Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.
    Noe MH; Rosenbach M; Hubbard RA; Mostaghimi A; Cardones AR; Chen JK; Cotliar J; Davis MDP; Dominguez A; Fox LP; Hughey LC; Kaffenberger BH; Kroshinsky D; Kwong BY; Miller DD; Musiek A; Ortega-Loayza AG; Sharon VR; Shinkai K; Summers EM; Wanat KA; Wetter DA; Worswick S; Margolis DJ; Gelfand JM; Micheletti RG
    JAMA Dermatol; 2019 Apr; 155(4):448-454. PubMed ID: 30840032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality.
    Roujeau JC; Bastuji-Garin S
    Ther Adv Drug Saf; 2011 Jun; 2(3):87-94. PubMed ID: 25083204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Miyamoto Y; Ohbe H; Kumazawa R; Matsui H; Fushimi K; Yasunaga H; Ohta B
    JAMA Dermatol; 2023 May; 159(5):481-487. PubMed ID: 36884227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic kidney disease is potentially an independent prognostic factor for death in Stevens-Johnson syndrome and toxic epidermal necrolysis patients.
    Rattanakaemakorn P; Palakornkitti P; Pinyowiwat P; Jedee P; Thadanipon K
    Front Med (Lausanne); 2022; 9():939210. PubMed ID: 36091688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study.
    Kridin K; Brüggen MC; Chua SL; Bygum A; Walsh S; Nägeli MC; Kucinskiene V; French L; Tétart F; Didona B; Milpied B; Ranki A; Salavastru C; Brezinová E; Divani-Patel S; Lorentzen T; Nagel JL; Valiukeviciene S; Karpaviciute V; Tiplica GS; Oppel E; Oschmann A; de Prost N; Vorobyev A; Ingen-Housz-Oro S
    JAMA Dermatol; 2021 Oct; 157(10):1182-1190. PubMed ID: 34431984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Experience from a Tertiary Care Centre of South Rajasthan.
    Balai M; Meena M; Mittal A; Gupta LK; Khare AK; Mehta S
    Indian Dermatol Online J; 2021; 12(1):116-122. PubMed ID: 33768032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis.
    Torres-Navarro I; Briz-Redón Á; Botella-Estrada R
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):159-171. PubMed ID: 32946187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil : lymphocyte ratio is associated with disease severity and mortality in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Wang Q; Lan YP; Qi B; Yin L; Zhang LX; Liu W
    J Dermatol; 2021 Sep; 48(9):1394-1400. PubMed ID: 34060656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Torres-Navarro I; Briz-Redón Á; Botella-Casas G; Sahuquillo-Torralba A; Calle-Andrino A; de Unamuno-Bustos B; Piqueras-García J; Roca Ginés J; Magdaleno Tapial J; Alegre de Miquel V; Botella-Estrada R
    J Dermatol; 2020 Oct; 47(10):1182-1186. PubMed ID: 32856355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
    Schneider JA; Cohen PR
    Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.